A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose
 is to learn more about how tirzepatide affects body weight. The study has two phases: A main
 phase and an extension phase. The main phase of the study will last 72 weeks (14 visits).
 Participants with prediabetes will continue in the extension for another 2 years.
Inclusion Criteria:

 -  Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and
 previous diagnosis with at least one of the following comorbidities: hypertension,
 dyslipidemia, obstructive sleep apnea, cardiovascular disease

 -  History of at least one unsuccessful dietary effort to lose body weight

 Exclusion Criteria:

 -  Diabetes mellitus

 -  Change in body weight greater than 5 kg within 3 months prior to starting study

 -  Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of
 obesity

 -  History of pancreatitis

 -  Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine
 neoplasia syndrome type 2 (MEN-2)

 -  History of significant active or unstable major depressive disorder (MDD) or other
 severe psychiatric disorder within the last 2 years

 -  Any lifetime history of a suicide attempt